These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22190396)

  • 1. Comparison between Elecsys HBsAg II and architect HBsAg QT assays for quantification of hepatitis B surface antigen among patients coinfected with HIV and hepatitis B virus.
    Maylin S; Boyd A; Delaugerre C; Zoulim F; Lavocat F; Simon F; Girard PM; Lacombe K
    Clin Vaccine Immunol; 2012 Feb; 19(2):242-8. PubMed ID: 22190396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantification of hepatitis B e antigen between Elecsys HBeAg and Architect HBeAg assays among patients infected with hepatitis B virus.
    Maylin S; Boyd A; Martinot-Peignoux M; Delaugerre C; Bagnard G; Lapalus M; Zoulim F; Lavocat F; Marcellin P; Simon F; Girard PM; Lacombe K
    J Clin Virol; 2013 Apr; 56(4):306-11. PubMed ID: 23369885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.
    Wursthorn K; Jaroszewicz J; Zacher BJ; Darnedde M; Raupach R; Mederacke I; Cornberg M; Manns MP; Wedemeyer H
    J Clin Virol; 2011 Apr; 50(4):292-6. PubMed ID: 21273117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of hepatitis B surface antigen and E antigen: correlation between Elecsys and architect assays.
    Zhou B; Liu M; Lv G; Zheng H; Wang Y; Sun J; Hou J
    J Viral Hepat; 2013 Jun; 20(6):422-9. PubMed ID: 23647959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison between Elecsys HBsAg II and Architect assays for quantification of serum hepatitis B surface antigen in Chinese patients with chronic hepatitis B.
    Liu WW; Wang AZ; Xie FY; Hu TT; Zhong Q; Huang S
    Clin Lab; 2015; 61(1-2):141-7. PubMed ID: 25807647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients.
    Liao CC; Hsu CW; Gu PW; Yeh CT; Lin SM; Chiu CT
    Biomed J; 2015; 38(3):250-6. PubMed ID: 25355387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of hepatitis B surface and envelope antigen and prediction of treatment response to tenofovir in antiretroviral-experienced HIV-hepatitis B virus-infected patients.
    Maylin S; Boyd A; Lavocat F; Gozlan J; Lascoux-Combe C; Miailhes P; Lassel L; Delaugerre C; Girard PM; Zoulim F; Lacombe K
    AIDS; 2012 May; 26(8):939-49. PubMed ID: 22333748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.
    Matthews GV; Ali RJ; Avihingsanon A; Amin J; Hammond R; Bowden S; Lewin SR; Sasadeusz J; Littlejohn M; Locarnini SL; Ruxrungtham K; Dore GJ
    PLoS One; 2013; 8(4):e61297. PubMed ID: 23593455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV.
    Zoutendijk R; Zaaijer HL; de Vries-Sluijs TE; Reijnders JG; Mulder JW; Kroon FP; Richter C; van der Eijk AA; Sonneveld MJ; Hansen BE; de Man RA; van der Ende ME; Janssen HL
    J Infect Dis; 2012 Sep; 206(6):974-80. PubMed ID: 22782950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
    Boyd A; Maylin S; Moh R; Mahjoub N; Gabillard D; Eholié SP; Danel C; Anglaret X; Zoulim F; Girard PM; Delaugerre C; Lacombefor K;
    J Gastroenterol Hepatol; 2016 Mar; 31(3):634-44. PubMed ID: 26313291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
    Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
    J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the Elecsys HBsAg II Assay and the Architect Assay for Quantification of hepatitis B surface antigen in patients with chronic hepatitis B.
    Karagoz E; Selek MB; Tanoglu A; Hatipoglu M; Ulçay A; Turhan V
    Infez Med; 2016 Dec; 24(4):287-292. PubMed ID: 28011963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of hepatitis B surface and "e" antigen quantification during extensive treatment with tenofovir in patients co-infected with HIV-HBV.
    Boyd A; Maylin S; Gozlan J; Delaugerre C; Simon F; Girard PM; Lacombe K
    Liver Int; 2015 Mar; 35(3):795-804. PubMed ID: 24606220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution.
    Liu TW; Yeh ML; Huang CF; Lin IL; Huang JF; Dai CY; Chen YL; Chuang WL; Yu ML
    Kaohsiung J Med Sci; 2015 Jan; 31(1):26-33. PubMed ID: 25600917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The kinetics of the hepatitis B surface antigen level after the initiation of antiretroviral therapy for hepatitis B virus and human immunodeficiency virus coinfected patients.
    Mitsumoto F; Murata M; Ura K; Takayama K; Hiramine S; Shimizu M; Toyoda K; Ogawa E; Furusyo N; Hayashi J
    J Infect Chemother; 2015 Apr; 21(4):264-71. PubMed ID: 25596071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: correlation with the ARCHITECT quantitative assays.
    Burdino E; Ruggiero T; Proietti A; Milia MG; Olivero A; Caviglia GP; Marietti M; Rizzetto M; Smedile A; Ghisetti V
    J Clin Virol; 2014 Aug; 60(4):341-6. PubMed ID: 24930708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.
    Huang AJ; Núñez M
    J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of hepatitis B markers in Senegalese HIV-1-infected patients.
    Lô G; Sow-Sall A; Diop-Ndiaye H; Mandiouba NC; Thiam M; Diop F; Ndiaye O; Gueye SB; Seck SM; Dioura AA; Mbow M; Gaye-Diallo A; Mboup S; Touré-Kâne C
    J Med Virol; 2016 Mar; 88(3):461-5. PubMed ID: 26252424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B.
    Sonneveld MJ; Rijckborst V; Boucher CA; Zwang L; Beersma MF; Hansen BE; Janssen HL
    J Clin Virol; 2011 Jul; 51(3):175-8. PubMed ID: 21592855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment.
    Li X; Xu L; Lu L; Liu X; Yang Y; Wu Y; Zhu T; Li X; Li Y; Song X; Han Y; Lyu W; Cao W; Li T
    J Transl Med; 2024 Oct; 22(1):901. PubMed ID: 39367456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.